iBio, Inc. Form 10-Q Summary
Reporting period: Three and nine months ended March 31, 2014. The provided filing text identifies the period as fiscal 2014 third quarter, notwithstanding the request metadata referencing “2013 Q3.” Financial statements are unaudited and presented under U.S. GAAP.
Business Context
iBio is a biotechnology company commercializing plant-based protein expression technologies, including the iBioLaunch platform for vaccines and therapeutic proteins and the iBioModulator platform for vaccine enhancement. Its strategy emphasizes licensing, collaborations, and advancing selected product candidates. The company also has subsidiaries intended to support defense applications and activities in Brazil, although neither subsidiary had activity through March 31, 2014.
Financial Results and Position
| Metric | Three Months Ended March 31, 2014 | Nine Months Ended March 31, 2014 | Comparable Prior Period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 and $390,000, respectively |
| Operating expenses | $1.294 million | $2.689 million | $1.860 million and $5.755 million |
| Operating loss | $1.294 million | $2.689 million | $1.860 million and $5.365 million |
| Net loss | $1.279 million | $2.524 million | $1.758 million and $4.881 million |
| Loss per share | $0.02 | $0.04 | $0.04 and $0.10 |
| Cash flow from operations | Not separately provided | $(3.432) million | $(3.940) million |
Because revenue was zero, a meaningful revenue margin cannot be calculated. The company had $4.333 million of cash at March 31, 2014, compared with $4.414 million at June 30, 2013. Total assets were $8.214 million, including $2.675 million of net intangible assets. Current liabilities were $1.213 million; the filing does not identify outstanding conventional debt. Stockholders’ equity was $7.001 million, and the accumulated deficit was $40.060 million.
Investing activities used $200,000 during the nine-month period, principally for intangible assets. Financing activities provided $3.551 million, consisting primarily of $3.1 million from warrant exercises and approximately $480,000 from a private placement, net of capital-raising costs.
Material Changes Versus Prior Comparable Period
- Quarterly revenue remained at zero. Nine-month revenue declined from approximately $390,000 to zero because the company and its partners were awaiting Brazilian government approval of an amendment to the FioCruz yellow fever vaccine work plan.
- Quarterly research and development expense declined to $343,000 from $631,000, primarily because of lower Fraunhofer subcontracting activity. Nine-month reported research and development expense declined to $1.480 million from $2.464 million, including a $1.041 million credit related to the Fraunhofer settlement.
- Quarterly general and administrative expense declined to $951,000 from $1.229 million. Nine-month reported general and administrative expense declined to $2.950 million from $3.291 million, including a $700,000 settlement-related credit.
- The Fraunhofer settlement released approximately $2.9 million of liabilities, eliminated certain minimum payment and royalty obligations, extended the technology transfer agreement through December 31, 2015, and replaced prior guaranteed payments with a requirement to engage Fraunhofer for at least $3 million of research and development work by that date.
- Cash used in operations improved to $3.432 million from $3.940 million, while financing shifted from no reported proceeds in the prior period to $3.551 million.
- Shares outstanding increased to 65.642 million from 56.692 million at June 30, 2013, reflecting 7.75 million shares issued upon warrant exercises and 1.2 million shares issued in the private placement.
- Approximately 8.876 million warrants expired, and approximately 8.750 million stock options were outstanding at March 31, 2014. Potential future dilution remains material.
Guidance, Outlook, Risks, and Unusual Items
- Management expected cash on hand at March 31, 2014 to support activities through the quarter ending March 31, 2015, but stated that the company expects continuing losses and will require additional financing or collaboration proceeds thereafter.
- Management plans to fund operations through cash on hand, additional equity or other securities, and license or collaboration arrangements. Financing may be unavailable or unfavorable and additional equity could significantly dilute shareholders.
- The filing states that the company’s accumulated deficit, negative operating cash flow, limited cash resources, and dependence on additional financing raise substantial doubt about its ability to continue as a going concern.
- If financing is unavailable, iBio may delay, reduce, or discontinue development and commercialization activities, accept less favorable collaborations, relinquish rights, or potentially cease operations.
- iBio remained dependent on Fraunhofer as a significant vendor. Approximately $1.0 million was payable to Fraunhofer at March 31, 2014, and the company had committed approximately $600,000 of the required $3 million of future research and development work.
- The company acquired exclusive worldwide rights to certain fibrosis-related patents from a U.S. university in January 2014. Obligations include fees, royalties, milestones, and development diligence requirements; a New Drug Application milestone is due December 1, 2015.
- The filing reports no impairment charges, no income tax expense, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2014.
Investor Verification Checklist
- Verify the status and economics of the FioCruz yellow fever vaccine contract amendment and the timing of any related revenue.
- Confirm the company’s post-quarter cash balance, operating cash burn, and actual financing needs relative to the stated runway.
- Review the going-concern disclosure and assess whether additional financing was subsequently obtained and on what terms.
- Review the Fraunhofer settlement, remaining $3 million research commitment, and any related payment or performance obligations.
- Assess dilution from outstanding options, warrants, and potential future equity offerings.
- Track development, regulatory, and funding milestones for the fibrosis-related licensed technology and other product candidates.